Virgo Health’s Post

Transcript

Ki is contributing to the prevention agenda by investing significantly in Rd. Working in rare diseases is a really complex area and it takes a long time often to find treatments and cures, diagnostic tools that really satisfy the rare agenda and help patients. But part of that is talking to patients and collaborating with them, looking for partnerships. So often in rare we work with patients and patient groups to look at what we should be studying, how the trial should be set up and contributing. That way, there's lots of things industry can do to support health literacy and prevention. In the UK, one of the government's big shifts is about sickness to prevention from sickness to prevention from hospitals to community. We can reinforce that by telling stories of people whose lives have been changed by the support that they're given in the communities and the healthcare they receive. At that level. We can work with our colleagues to make sure that we identify people who've had early treatment through. Diagnosis who've been visited at home because they can't get out to one of the stores, who've been able to use technology in a really innovative way. We can tell those stories to encourage people to develop their own catholicity.